trial

Inpatient Evaluation of Adults With Schizophrenia

NCTId NCT00001247
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase — · Completed
Enrollment 648 (actual)
Sponsored by National Institute of Mental Health (NIMH)
Synthesized from structured facts only — each point cited above.

Design & status

Phase
—
Status
Completed
Enrollment
648 (actual)
Study type
Observational
Allocation
—
Model
—
Masking
—
Start
1989-09-15
Primary completion
—
Eligibility
ALL · 18 Years · 120 Years

Interventions & indications

Drugs
Sirolimus

Sponsors

National Institute of Mental Health (NIMH)Lead Sponsor

Investigators

1
Daniel H. Mathalon, Ph.D., M.D.Principal Investigator

Sites

1 total
Bethesda, United States

Facts & assertions

3 sourced
Enrollment
648
Phase
NA
Status
COMPLETED
relationships
The graph out of here
drug
Sirolimus
drug
lead_sponsor
National Institute of Mental Health (NIMH)
company
indication
Schizophrenia
indication
Schizophrenia
indication
Psychotic Disorders
indication
investigator
Daniel H. Mathalon, Ph.D., M.D.
person